Detection of Human alpha ‑N‑acetylgalactosaminidase/NAGA by Western Blot. Western blot shows lysates of human placenta tissue. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human alpha ‑N‑acetylgalactosaminidase/NAGA Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6717) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for alpha ‑N‑acetylgalactosaminidase/NAGA at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
alpha ‑N‑acetylgalactosaminidase/NAGA in HeLa Human Cell Line. alpha ‑N‑acetylgalactosaminidase/NAGA was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Sheep Anti-Human alpha ‑N‑acetylgalactosaminidase/ NAGA Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6717) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (red; Catalog # NL010) and counterstained with DAPI (blue). Specific staining was localized to lysosomes. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Preparation and Storage
Sterile PBS to a final concentration of 0.2 mg/mL.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
NAGA is a lysosomal alpha -N-acetylgalactosaminidase that cleaves non-reducing alpha -N-acetylgalactosaminyl moieties from glycoconjugates (1). Mature NAGA has 394 amino acids and is trafficked to the lysosome via the mannose-6-phosphate receptor‑mediated pathway (2). The enzyme is a retaining exoglycosidase, where both the substrate and product of the enzymatic reaction have the same anomeric configuration (3). Deficiency in NAGA results in increased urinary excretion and tissue accumulation of glycopeptides and oligosaccharides containing terminal alpha ‑N‑acetylgalactosaminyl moieties (4), manifesting as Schindler’s disease, an autosomal recessive disease with neuroaxonal dystrophy and other neurological symptoms (5). The enzyme can be used to remove alpha ‑N‑acetylgalactosaminyl residues present on red blood cells thus converting blood type A to blood type O (6, 7, 8).
Wang, A.M. et al. (1990) J. Biol. Chem. 265:21859.
Sweeley, C.C. et al. (1983) Arch. Biochem. Biophys. 223:158.
Garman, S.C. et al. (2002) Structure. 10:425.
Eng, C.M. et al. (2001) N. Engl. J. Med. 345:9.
Wang, A.M. et al. (1990) J. Clin. Invest. 86:1752.
Liu, Q.P. et al. (2007) Nature Biotechnol. 25:454.
Calcutt, M. J. et al. (2002) FEMS Microbiol. Lett. 214:77.
Zhu, A. et al. (1996) Arch. Biochem. Biophys. 327:324.
Have you used Human alpha ‑N‑acetylgalactosaminidase/ NAGA Antibody?
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.